Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1999-2-16
|
pubmed:abstractText |
High levels of soluble lymphocyte antigens have been described in a large number of tumors and, particularly, in hematopoietic neoplasms. As previously reported, many antitumor immune responses are IL-2 dependent: clinical observations indicate that a worse survival in advanced tumor patients is related with a decrease of soluble IL-2 levels. A soluble form of CD8 has been described: as found in Hodgkin's disease and acute lymphoblastic leukemia, sCD8 levels have a prognostic value. To explain the significance of these soluble molecules in solid tumors, we a) determinated sIL-2R and sCD8 in 84 patients; b) correlated the expression of p55 chain of IL-2R and CD8 antigen on the cell-surface of peripheral lymphocytes to sIL-2R and sCD8 levels; c) analyzed endogenous IL-2R levels in patients with lung cancer. An increase of sIL-2R was found in 82% of cases, while high levels of sCD8 were observed in 32%; no correlation was observed between sIL-2R and the expression of p55 on the surface of peripheral lymphocytes: IL-2 levels in patients with NSCLC were significatively reduced, when compared to healthy controls, with an inverse relationship between endogenous IL-2 concentration and sIL-2R levels. Whatever may be the physiopathological mechanism of the increase of sIL-2 observed in solid tumors, this rise may contribute to the immunodepression correlated to neoplastic disease. Therefore, higher levels of sIL-2R/IL-2 ratio has a negative biologic prognostic significance. We think that determinating CD8 antigen in the serum can offer a more sensitive and specific measurement of activation of suppressor/cytotoxic T-lymphocytes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1107-3756
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
75-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9854147-Adult,
pubmed-meshheading:9854147-Aged,
pubmed-meshheading:9854147-Antigens, CD8,
pubmed-meshheading:9854147-Antigens, Neoplasm,
pubmed-meshheading:9854147-Antigens, Surface,
pubmed-meshheading:9854147-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:9854147-Female,
pubmed-meshheading:9854147-Humans,
pubmed-meshheading:9854147-Lung Neoplasms,
pubmed-meshheading:9854147-Lymphocyte Activation,
pubmed-meshheading:9854147-Male,
pubmed-meshheading:9854147-Middle Aged,
pubmed-meshheading:9854147-Neoplasm Staging,
pubmed-meshheading:9854147-Receptors, Interleukin-2,
pubmed-meshheading:9854147-Solubility
|
pubmed:year |
1998
|
pubmed:articleTitle |
Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
|
pubmed:affiliation |
Division of Medical Oncology, Department of Internal and Experimental Medicine, II University School of Medicine of Naples, Naples, Italy.
|
pubmed:publicationType |
Journal Article
|